Edgewise Therapeutics, Inc. EWTX EBITDA

EBITDA at other companies

Bristol-Myers SquibbBMY

$4.68B+68.1%

Sarepta Therapeutics, Inc.SRPT

$23.7M-81.3%

CytokineticsCYTK

-$175.54M-60.7%

PTC TherapeuticsPTCT

$60.37M-93.8%

Dyne Therapeutics, Inc.DYN

-$124.73M-2.3%

Solid Biosciences Inc.SLDB

-$56.99M-38.0%

FAQ

What is Edgewise Therapeutics, Inc.'s EBITDA?

Edgewise Therapeutics, Inc. (EWTX) reported EBITDA of -$53.58M in Q1 2026.

How has Edgewise Therapeutics, Inc.'s EBITDA changed year-over-year?

Edgewise Therapeutics, Inc.'s EBITDA decreased by 17.9% year-over-year, from -$45.45M to -$53.58M.

What is the long-term trend for Edgewise Therapeutics, Inc.'s EBITDA?

Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s EBITDA has grown at a 44.9% compound annual growth rate (CAGR), from -$42.91M to -$189.37M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.